Drugs / Flortaucipir
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02167594 | Aug 2014 → Jul 2016 | corticobasal degeneration disorder, progressive supranuclear palsy | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07007208 | Feb 2026 → Jan 2029 expected | Alzheimer disease | University Hospital, Toulouse | Recruiting | No outcome recorded |
| Phase 2 | NCT02795780 | Aug 2016 → Aug 2017 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02016560 | Dec 2013 → Jul 2017 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02516046 | Sep 2015 → Jun 2018 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flortaucipir | “TEP exam using tau-specific tracer ( Flortaucipir, unique dose 360 MBq)” NCT07007208 ↗ |
| Known as | Flortaucipir F18 | “Drug: Flortaucipir F18” NCT02167594 ↗1“Drug: Flortaucipir F18” NCT02516046 ↗ |
| Modality | Diagnostic / imaging agent | “Flortaucipir positron emission tomography (PET) scans” PMID 33587110 ↗ Apr 2021 |
| Route | Intravenous | “IV injection, 370 megabecquerel (MBq) (10 mCi)” NCT02167594 ↗ |